Abstract:We report the development of novel cannabinergic probes that can stabilize the cannabinoid receptors (CBRs) through tight binding interactions. Ligand design involves the introduction of select groups at a judiciously chosen position within the classical hexahydrocannabinol template (monofunctionalized probes). Such groups include the electrophilic isothiocyanato, the photoactivatable azido, and the polar cyano moieties. These groups can also be combined to produce bifunctionalized probes potentially capable of interacting at two distinct sites within the CBR-binding domains. These novel compounds display remarkably high binding affinities for CBRs and are exceptionally potent agonists. A key ligand (27a, AM11245) exhibits exceptionally high potency in both in vitro and in vivo assays and was designated as "megagonist," a property attributed to its tight binding profile. By acting both centrally and peripherally, 27a distinguishes itself from our previously reported "megagonist" AM841, whose functions are restricted to the periphery.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02053?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02053</a>.Experimental procedures, spectroscopic, analytical, and physical data for 12a–b, 13a–b, 14a–c, 15a–c, 16a–c, 17a–c, 18a–c, 19a–c, 20a–c, 21a–c, 22a–c, 23a–c, 24a–c, 25a–c, 26a–c, and 27a–c; saturation binding curves using [3H]CP-55,940 for CB1 and CB2 receptors pre-incubated with the 25a–c, 26a–c, 27a–c, 31c, 32c, 33c, and 34c; and HPLC traces of 25a, 26c, 27b, and 31c (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02053/suppl_file/jm0c02053_si_001.pdf">PDF</a>).Molecular formula strings and biochemical data of 25a–c, 26a–c, 27a–c, 31c, 32c, 33c, and 34c (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02053/suppl_file/jm0c02053_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Identification of Novel Antagonists Targeting Cannabinoid Receptor 2 Using a Multi-Step Virtual Screening Strategy

Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.

Large library docking for cannabinoid-1 receptor agonists with reduced side effects

Modeling, Molecular Dynamics Simulation, and Mutation Validation for Structure of Cannabinoid Receptor 2 Based on Known Crystal Structures of GPCRs

Identification of New Potent A1 Adenosine Receptor Antagonists Using a Multistage Virtual Screening Approach

In silico investigation of interactions between human cannabinoid receptor-1 and its antagonists

Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects

Discovery of Novel Dual Adenosine A1/A2A Receptor Antagonists Using Deep Learning, Pharmacophore Modeling and Molecular Docking.

Licabeds Ii. Modeling of Ligand Selectivity for G-Protein-Coupled Cannabinoid Receptors

The progress of small molecules against cannabinoid 2 receptor (CB2R)

Visualization of membrane localization and functional state of CB2R pools by matched agonist and inverse agonist probe pairs

Retrieving Novel C5aR Antagonists Using a Hybrid Ligand-Based Virtual Screening Protocol Based on SVM Classification and Pharmacophore Models.

Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists

A Combination of 2D Similarity Search, Pharmacophore, and Molecular Docking Techniques for the Identification of Vascular Endothelial Growth Factor Receptor-2 Inhibitors

Crystal Structure of the Human Cannabinoid Receptor CB2

Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking

Discovery of novel TRPV1 modulators through machine learning‐based molecular docking and molecular similarity searching

A unique ligand-steered strategy for CC chemokine receptor 2 homology modeling to facilitate structure-based virtual screening

Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation.

Amidoalkylindoles as Potent and Selective Cannabinoid Type 2 Receptor Agonists with in Vivo Efficacy in a Mouse Model of Multiple Sclerosis.